J Cancer 2019; 10(11):2434-2442. doi:10.7150/jca.30659

Review

Role of p53 Family Proteins in Metformin Anti-Cancer Activities

Yong Yi, Wenhua Zhang, Jianqiao Yi, Zhi-Xiong Xiao

Yong Yi, Wenhua Zhang, JianqiaoYi and Zhi-Xiong Xiao

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Yi Y, Zhang W, Yi J, Xiao ZX. Role of p53 Family Proteins in Metformin Anti-Cancer Activities. J Cancer 2019; 10(11):2434-2442. doi:10.7150/jca.30659. Available from http://www.jcancer.org/v10p2434.htm

File import instruction

Abstract

Metformin has been used as therapy for type 2 diabetes for many years. Clinical and basic evidence as indicated that metformin has anti-cancer activities. It has been well-established that metformin activates AMP-activated protein kinase (AMPK), which in turn regulates energy homeostasis. However, the mechanistic aspects of metformin anti-cancer activity remain elusive. p53 family proteins, including p53, p63 and p73, have diverse biological functions, including regulation of cell growth, survival, development, senescence and aging. In this review, we highlight the evidence and mechanisms by which metformin inhibits cancer cell survival and tumor growth. We also aimed to discuss the role of p53 family proteins in metformin-mediated suppression of cancer growth and survival.

Keywords: metformin, AMPK, p53, p63, p73, cancer